Cargando…

Progress and prospects on vaccine development against monkeypox infection

The monkeypox virus (MPOX) is an uncommon zoonotic illness brought on by an orthopoxvirus (OPXV). MPOX can occur with symptoms similar to smallpox. Since April 25, 2023, 110 nations have reported 87,113 confirmed cases and 111 fatalities. Moreover, the outspread prevalence of MPOX in Africa and a cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Saadh, Mohamed J., Ghadimkhani, Tahmineh, Soltani, Narges, Abbassioun, Arian, Daniel Cosme Pecho, Renzon, taha, Ali, Jwad Kazem, Tareq, Yasamineh, Saman, Gholizadeh, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186953/
https://www.ncbi.nlm.nih.gov/pubmed/37201635
http://dx.doi.org/10.1016/j.micpath.2023.106156
_version_ 1785042658517843968
author Saadh, Mohamed J.
Ghadimkhani, Tahmineh
Soltani, Narges
Abbassioun, Arian
Daniel Cosme Pecho, Renzon
taha, Ali
Jwad Kazem, Tareq
Yasamineh, Saman
Gholizadeh, Omid
author_facet Saadh, Mohamed J.
Ghadimkhani, Tahmineh
Soltani, Narges
Abbassioun, Arian
Daniel Cosme Pecho, Renzon
taha, Ali
Jwad Kazem, Tareq
Yasamineh, Saman
Gholizadeh, Omid
author_sort Saadh, Mohamed J.
collection PubMed
description The monkeypox virus (MPOX) is an uncommon zoonotic illness brought on by an orthopoxvirus (OPXV). MPOX can occur with symptoms similar to smallpox. Since April 25, 2023, 110 nations have reported 87,113 confirmed cases and 111 fatalities. Moreover, the outspread prevalence of MPOX in Africa and a current outbreak of MPOX in the U.S. have made it clear that naturally occurring zoonotic OPXV infections remain a public health concern. Existing vaccines, though they provide cross-protection to MPOX, are not specific for the causative virus, and their effectiveness in the light of the current multi-country outbreak is still to be verified. Furthermore, as a sequel of the eradication and cessation of smallpox vaccination for four decades, MPOX found a possibility to re-emerge, but with distinct characteristics. The World Health Organization (WHO) suggested that nations use affordable MPOX vaccines within a framework of coordinated clinical effectiveness and safety evaluations. Vaccines administered in the smallpox control program and conferred immunity against MPOX. Currently, vaccines approved by WHO for use against MPOX are replicating (ACAM2000), low replicating (LC16m8), and non-replicating (MVA-BN). Although vaccines are accessible, investigations have demonstrated that smallpox vaccination is approximately 85% efficient in inhibiting MPOX. In addition, developing new vaccine methods against MPOX can help prevent this infection. To recognize the most efficient vaccine, it is essential to assess effects, including reactogenicity, safety, cytotoxicity effect, and vaccine-associated side effects, especially for high-risk and vulnerable people. Recently, several orthopoxvirus vaccines have been produced and are being evaluated. Hence, this review aims to provide an overview of the efforts dedicated to several types of vaccine candidates with different strategies for MPOX, including inactivated, live-attenuated, virus-like particles (VLPs), recombinant protein, nucleic acid, and nanoparticle-based vaccines, which are being developed and launched.
format Online
Article
Text
id pubmed-10186953
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101869532023-05-16 Progress and prospects on vaccine development against monkeypox infection Saadh, Mohamed J. Ghadimkhani, Tahmineh Soltani, Narges Abbassioun, Arian Daniel Cosme Pecho, Renzon taha, Ali Jwad Kazem, Tareq Yasamineh, Saman Gholizadeh, Omid Microb Pathog Article The monkeypox virus (MPOX) is an uncommon zoonotic illness brought on by an orthopoxvirus (OPXV). MPOX can occur with symptoms similar to smallpox. Since April 25, 2023, 110 nations have reported 87,113 confirmed cases and 111 fatalities. Moreover, the outspread prevalence of MPOX in Africa and a current outbreak of MPOX in the U.S. have made it clear that naturally occurring zoonotic OPXV infections remain a public health concern. Existing vaccines, though they provide cross-protection to MPOX, are not specific for the causative virus, and their effectiveness in the light of the current multi-country outbreak is still to be verified. Furthermore, as a sequel of the eradication and cessation of smallpox vaccination for four decades, MPOX found a possibility to re-emerge, but with distinct characteristics. The World Health Organization (WHO) suggested that nations use affordable MPOX vaccines within a framework of coordinated clinical effectiveness and safety evaluations. Vaccines administered in the smallpox control program and conferred immunity against MPOX. Currently, vaccines approved by WHO for use against MPOX are replicating (ACAM2000), low replicating (LC16m8), and non-replicating (MVA-BN). Although vaccines are accessible, investigations have demonstrated that smallpox vaccination is approximately 85% efficient in inhibiting MPOX. In addition, developing new vaccine methods against MPOX can help prevent this infection. To recognize the most efficient vaccine, it is essential to assess effects, including reactogenicity, safety, cytotoxicity effect, and vaccine-associated side effects, especially for high-risk and vulnerable people. Recently, several orthopoxvirus vaccines have been produced and are being evaluated. Hence, this review aims to provide an overview of the efforts dedicated to several types of vaccine candidates with different strategies for MPOX, including inactivated, live-attenuated, virus-like particles (VLPs), recombinant protein, nucleic acid, and nanoparticle-based vaccines, which are being developed and launched. Elsevier Ltd. 2023-07 2023-05-16 /pmc/articles/PMC10186953/ /pubmed/37201635 http://dx.doi.org/10.1016/j.micpath.2023.106156 Text en © 2023 Elsevier Ltd. All rights reserved. Elsevier has created a Monkeypox Information Center (https://www.elsevier.com/connect/monkeypox-information-center) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
spellingShingle Article
Saadh, Mohamed J.
Ghadimkhani, Tahmineh
Soltani, Narges
Abbassioun, Arian
Daniel Cosme Pecho, Renzon
taha, Ali
Jwad Kazem, Tareq
Yasamineh, Saman
Gholizadeh, Omid
Progress and prospects on vaccine development against monkeypox infection
title Progress and prospects on vaccine development against monkeypox infection
title_full Progress and prospects on vaccine development against monkeypox infection
title_fullStr Progress and prospects on vaccine development against monkeypox infection
title_full_unstemmed Progress and prospects on vaccine development against monkeypox infection
title_short Progress and prospects on vaccine development against monkeypox infection
title_sort progress and prospects on vaccine development against monkeypox infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186953/
https://www.ncbi.nlm.nih.gov/pubmed/37201635
http://dx.doi.org/10.1016/j.micpath.2023.106156
work_keys_str_mv AT saadhmohamedj progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT ghadimkhanitahmineh progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT soltaninarges progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT abbassiounarian progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT danielcosmepechorenzon progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT tahaali progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT jwadkazemtareq progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT yasaminehsaman progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection
AT gholizadehomid progressandprospectsonvaccinedevelopmentagainstmonkeypoxinfection